Filing Flows › Heron Therapeutics (HRTX) › CINVANTI revenue
Heron Therapeutics (HRTX) CINVANTI revenue by quarter
Heron Therapeutics' CINVANTI revenue was $21.8M in Q2 2026 (second quarter 2026), +6% from Q1 2026. Over the last 7 quarters it ranged from $20.5M (Q1 2026) to $26.9M (Q4 2024).
| Quarter | CINVANTI revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $21.8M | +6% | -10% |
| Q1 2026 | $20.5M | -10% | -20% |
| Q4 2025 | $22.9M | -4% | -15% |
| Q3 2025 | $24.0M | -0.8% | — |
| Q2 2025 | $24.1M | -6% | — |
| Q1 2025 | $25.7M | -4% | — |
| Q4 2024 | $26.9M | — | — |
Q2 2026 at a glance
Heron Therapeutics, Q2 2026: revenue $37.7M (+1% year over year), operating margin -5.4%, net loss $5.5M, operating cash flow −$2.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Heron Therapeutics' CINVANTI revenue?
Heron Therapeutics' CINVANTI revenue was $21.8M in Q2 2026 (second quarter 2026), +6% from Q1 2026.
How has Heron Therapeutics' CINVANTI revenue changed?
Over the last 7 quarters it ranged from $20.5M (Q1 2026) to $26.9M (Q4 2024).